Covid-19 and drug therapy, what we learned

Alessio Provenzani; Piera Polidori

doi:10.1007/s11096-020-01049-6

Covid-19 and drug therapy, what we learned

Alessio Provenzani, Piera Polidori

ISMETT

Research output: Contribution to journal › Review article › peer-review

Abstract

COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.

Original language	English
Pages (from-to)	833-836
Number of pages	4
Journal	International Journal of Clinical Pharmacy
Volume	42
Issue number	3
DOIs	https://doi.org/10.1007/s11096-020-01049-6
Publication status	Published - Jun 2020

Keywords

Antiviral Agents/pharmacology
Betacoronavirus/drug effects
COVID-19
China
Coronavirus Infections/drug therapy
Humans
Pandemics
Pneumonia, Viral/drug therapy
SARS-CoV-2

Access to Document

10.1007/s11096-020-01049-6

Fingerprint Dive into the research topics of 'Covid-19 and drug therapy, what we learned'. Together they form a unique fingerprint.

Cite this

@article{f8beec9c5b9b4093bf4b4cb121e72c80,

title = "Covid-19 and drug therapy, what we learned",

abstract = "COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.",

keywords = "Antiviral Agents/pharmacology, Betacoronavirus/drug effects, COVID-19, China, Coronavirus Infections/drug therapy, Humans, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2",

author = "Alessio Provenzani and Piera Polidori",

year = "2020",

month = jun,

doi = "10.1007/s11096-020-01049-6",

language = "English",

volume = "42",

pages = "833--836",

journal = "International Journal of Clinical Pharmacy",

issn = "2210-7703",

publisher = "Springer Netherlands",

number = "3",

}

TY - JOUR

T1 - Covid-19 and drug therapy, what we learned

AU - Provenzani, Alessio

AU - Polidori, Piera

PY - 2020/6

Y1 - 2020/6

N2 - COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.

AB - COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.

KW - Antiviral Agents/pharmacology

KW - Betacoronavirus/drug effects

KW - COVID-19

KW - China

KW - Coronavirus Infections/drug therapy

KW - Humans

KW - Pandemics

KW - Pneumonia, Viral/drug therapy

KW - SARS-CoV-2

U2 - 10.1007/s11096-020-01049-6

DO - 10.1007/s11096-020-01049-6

M3 - Review article

C2 - 32382873

VL - 42

SP - 833

EP - 836

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 3

ER -